Sh. F. Erdes

Sh. F. Erdes

Auto-generated profile, based on publicly available information

Sh. F. Erdes

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
AMAnna Moltó
Anna Moltó
AEAdrien Etcheto
Adrien Etcheto
DHDésirée van der Heijde
Désirée van der Heijde
RLRobert Landewé
Robert Landewé
FBFilip van Den Bosch
Filip van Den Bosch
MDMaxime Dougados
Maxime Dougados
Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice. Objective To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative. Methods Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist. Statistical analysis The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study. Results The most frequent comorbidities were osteoporosis (13%) and gastroduodenal ulcer (11%). The most frequent risk factors were hypertension (34%), smoking (29%) and hypercholesterolaemia (27%). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8% (Taiwan) to 98% (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14%)), emphasising the suboptimal monitoring of comorbidities. Conclusions A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.

1 October 2013 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JSJoachim Sieper
Joachim Sieper
SSShankar Srinivasan
Shankar Srinivasan
OZOmid Zamani
Omid Zamani
HMHerman Mielants
Herman Mielants
DCDenis Choquette
Denis Choquette
NVNathan Vastesaeger
Nathan Vastesaeger
Objective To determine which of two referral strategies, when used by referring physicians for patients with chronic back pain (CBP), is superior for diagnosing axial spondyloarthritis (SpA) by rheumatologists across several countries. Methods Primary care referral sites in 16 countries were randomised (1 : 1) to refer patients with CBP lasting >3 months and onset before age 45 years to a rheumatologist using either strategy 1 (any of inflammatory back pain (IBP), HLA-B27 or sacroiliitis on imaging) or strategy 2 (two of the following: IBP, HLA-B27, sacroiliitis, family history of axial SpA, good response to non-steroidal anti-inflammatory drugs, extra-articular manifestations). The rheumatologist established the diagnosis. The primary analysis compared the proportion of patients diagnosed with definite axial SpA by referral strategy. Results Patients (N=1072) were referred by 278 sites to 64 rheumatologists: 504 patients by strategy 1 and 568 patients by strategy 2. Axial SpA was diagnosed in 35.6% and 39.8% of patients referred by these respective strategies (between-group difference 4.40%; 95% CI −7.09% to 15.89%; p=0.447). IBP was the most frequently used referral criterion (94.7% of cases), showing high concordance (85.4%) with rheumatologists' assessments, and having sensitivity and a negative predictive value of >85% but a positive predictive value and specificity of <50%. Combining IBP with other criteria (eg, sacroiliitis, HLA-B27) increased the likelihood for diagnosing axial SpA. Conclusions A referral strategy based on three criteria leads to a diagnosis of axial SpA in approximately 35% of patients with CBP and is applicable across countries and geographical locales with presumably different levels of expertise in axial SpA.

1 February 1995 in Spine
Verified
Journal Article
Closed access
NTNatalia V. Toroptsova
Natalia V. Toroptsova
LBLydia I. Benevolenskaya
Lydia I. Benevolenskaya
AKAlexander N. Karyakin
Alexander N. Karyakin
ISIgor L. Sergeev
Igor L. Sergeev
SEShandor Erdesz
Shandor Erdesz
A representative sample of 18- to 65-year-old workers from a machine-building factory was studied using a standardized questionnaire. To study the prevalence of low back pain syndrome among workers at an industrial enterprise and to estimate the association between low back pain syndrome and certain factors. This was a cross-sectional study of 800 workers (400 men and 400 women), who were invited to participate in the study. Seven-hundred-and-one (87.6%) persons took part in the study--339 (84.7%) men and 362 (90.5%) women. The life-time prevalence of low back pain complaints was 48.2%. The prevalence during the last year was 31.5%, and point prevalence was 11.5%. The number of patients with low back pain complaints increased with age. The duration of a low back pain episode was less than 2 weeks in 88.2% of the patients, and more than 12 weeks in only in 1.8% of the patients. Analysis of some social, individual, and professional factors revealed associations between low back pain and low level of education, marital status, absence of sports activity, intensity of smoking, and frequent lifting and bending during the work day. Our study revealed a high prevalence of low back pain among workers at an industrial enterprise. This low back pain was primarily of an acute nature.

4 September 2020 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
VMV. I. Mazurov
V. I. Mazurov
IGI. Z. Gaydukova
I. Z. Gaydukova
SESh. Erdes
Sh. Erdes
TDT. V. Dubinina
T. V. Dubinina
APA. M. Pristrom
A. M. Pristrom
AEA. V. Eremeeva
A. V. Eremeeva
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.Subjects and methods. BCD-085-5/ASTERA was a double-blind, multicenter, randomized, placebo-controlled, phase III study, which included 228 adult patients with active AS, persisting despite active treatment with NSAIDs. AS was considered active at BASDAI score ≥ 4.0. Patients were blindly randomized (1:1) to receive subcutaneous injections of NTK (120 mg) or placebo at weeks 0, 1, 2 and then every other week up to week 14. Starting from week 16 all patients from NTK group and patients from placebo group not achieving ASAS20 were switched to open label 120 mg NTK s/c once every two weeks. The total duration of treatment with NTK was 3 years.Results. Higher proportion of patients had ASAS40 response at week 16 (primary endpoint) in NTK arm compared to placebo (40,4 vs 2,6%, р <0,0001, 95% CI [27,4%; 48,1%]). Spinal pain subsided and laboratory inflammation markers decreased within one week after the first NTK injection. NTK safety profile was comparable to that of placebo. The most common for NTK adverse events were neutropenia (7,0%) and ALT increase (6,1%).Conclusion. Subcutaneous NTK at 120 mg dose demonstrated superior efficacy vs placebo, with fast onset of response and favorable safety profile when used in patients with ankylosing spondylitis.

23 April 2021 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
SESh. F. Erdes
Sh. F. Erdes
Well-established and some little-known treatments of axial spondyloarthritis / ankylosing spondylitis (AS), which have appeared in recent years are discussed, also discussed are emerging trends for AS treatment.

17 February 2024 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
VMV. I. Mazurov
V. I. Mazurov
SESh. F. Erdes
Sh. F. Erdes
IGI. Z. Gaydukova
I. Z. Gaydukova
TDT. V. Dubinina
T. V. Dubinina
APA. M. Pristrom
A. M. Pristrom
AEA. V. Eremeeva
A. V. Eremeeva
The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year period in patients with active AS.Material and methods. BCD-085-5/ASTERA – double-blind, multicenter, randomized phase III clinical trial that enrolled patients with active AS (BASDAI ≥4) and a back pain intensity ≥4 on a numeric rating scale with inefficacy or intolerance of non-steroidal anti-inflammatory drugs or biologic drugs. A total of 228 patients were randomized in a 1:1 ratio and assigned to either the NTK group or the placebo/NTK group. Starting at week 16, patients who did not achieve ASAS20 (20% improvement according to ASAS criteria) received NTK 120 mg once every 2 weeks in an open-label regimen. Patients who achieved ASAS20 response at week 52 in the NTK group and week 68 in the placebo/NTK group continued to receive NTK (120 mg every 2 weeks) until week 156 in the NTK group and until week 172 in the placebo/NTK group.Results and discussion. Over the course of three years of NTK use, most patients experienced a sustained decline in AS activity (according to ASDAS-CRP, BASDAI) with sustained response (ASAS20/40, ASAS5/6) to therapy. Most adverse events reported were mild to moderate. 36.7% of patients had adverse events, which were mainly laboratory abnormalities, blood and lymphatic system abnormalities and infectious complications.Conclusion. The clinical effect of NTK was maintained in most patients with AS over a three-year period, with no significant loss of response. NTK was well tolerated and the safety profile remained favorable.